Bayer Lifescience Center joined Versant Ventures to launch BlueRock, which will develop stem cell treatments for cardiovascular diseases and neurodegenerative disorders.
Pharmaceutical and chemical producer Bayer and venture capital firm Versant Ventures committed $225m in series A funding to launch a regenerative medicine startup called BlueRock Therapeutics yesterday.
BlueRock will use the funding to develop induced pluripotent stem cell (iPSC) treatments for several diseases, with an initial focus on cardiovascular diseases and neurodegenerative disorders.
The company has not disclosed where its head office will be based but it will conduct research and development operations in Toronto, Canada, and New York and…
